Clinical Trials Browser

Fibrosis, Hepatitis B, Hepatitis C, Carcinoma, Hepatocellular, Hypothermia, Liver Cirrhosis, Alcoholic, Renal Insufficiency, Chronic, Acute Kidney Injury, End Stage Liver Disease, Non-alcoholic Fatty Liver Disease

NCT04179773 2025-01-14

CHIMIOSE

Terminated

7 enrolled

Gastrointestinal

Fibrosis, Liver Cirrhosis, Neoplasms, Colorectal Neoplasms

NCT00375011 2022-12-20

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

Terminated

200 enrolled

Gastrointestinal

Fibrosis, Hepatitis C, Carcinoma, Hepatocellular

NCT04264754 2021-05-06

Characterization of Methylation Patterns in Hepatocellular Carcinoma

Terminated

120 enrolled

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Liver Neoplasms

NCT01486134 2020-05-13

ARMTICH

Phase NA Terminated

15 enrolled

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Liver Neoplasms, Recurrence

NCT02319200 2017-01-11

METFOVIR

Phase 3 Terminated

11 enrolled

Gastrointestinal

Death, Fibrosis, Carcinoma, Hepatocellular, Hepatitis C, Chronic

NCT01215565 2014-03-13

Fibrolam

Phase 2 Terminated

4 enrolled

Gastrointestinal

Fibrolamellar hepatocellular carcinoma, Adenocarcinoma, Carcinoma, Digestive System Neoplasms, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pathologic Processes

NCT00151671 2012-02-27

IMPACT

Phase 2/3 Terminated

35 enrolled

Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular, Liver Cirrhosis, Liver Neoplasms

Clinical Trials

MHALT

CHIMIOSE

Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics

Characterization of Methylation Patterns in Hepatocellular Carcinoma

ARMTICH

METFOVIR

Fibrolam

IMPACT